Re-treatment with high-dose prednisolone after rituximab infusion for childhood-onset steroid-resistant nephrotic syndrome

2014 ◽  
Vol 29 (7) ◽  
pp. 1291-1292 ◽  
Author(s):  
Shuichiro Fujinaga ◽  
Taichi Hara
2014 ◽  
Vol 9 (6) ◽  
pp. 1109-1116 ◽  
Author(s):  
Svjetlana Lovric ◽  
Humphrey Fang ◽  
Virginia Vega-Warner ◽  
Carolin E. Sadowski ◽  
Heon Yung Gee ◽  
...  

2015 ◽  
Vol 97 (4) ◽  
pp. 555-566 ◽  
Author(s):  
Noriko Miyake ◽  
Hiroyasu Tsukaguchi ◽  
Eriko Koshimizu ◽  
Akemi Shono ◽  
Satoko Matsunaga ◽  
...  

2008 ◽  
Vol 19 (10) ◽  
pp. 1871-1878 ◽  
Author(s):  
Aurélie Philippe ◽  
Fabien Nevo ◽  
Ernie L. Esquivel ◽  
Dalia Reklaityte ◽  
Olivier Gribouval ◽  
...  

2015 ◽  
Vol 55 (4) ◽  
pp. 194 ◽  
Author(s):  
Nina Lestari ◽  
Neti Nurani ◽  
Madarina Julia

Background Children with nephrotic syndrome need high-dose corticosteroids to achieve remission. Studies have estimated a 35-43% risk of obesity in these patients after corticosteroid treatment.Objective To determine the prevalence of obesity in children who received corticosteroids for nephrotic syndrome, and to compare the risk of obesity in children with steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS).Methods We performed a retrospective cohort study in 50 children with SSNS or SRNS who received corticosteroid treatment. Obesity was defined to be a BMI-for-age Z-score above +2.0 SD, according to the WHO Growth Reference 2007. Central obesity was defined to be a waist-to-height ratio > 0.50.Results The overall prevalence of obesity was 22%, with 29% and 14% in the SSNS and SRNS groups, respectively. The overall prevalence of central obesity was 50%, with 54% and 46% in the SSNS and SRNS groups, respectively. The cumulative steroid doses in this study were not significantly different between the SSNS and SRNS groups. There were also no significant differences between groups for risk of obesity (RR 2.53; 95%CI 0.58 to 10.99) or central obesity (RR 1.39; 95%CI 0.45 to 4.25).Conclusion In children with nephrotic syndrome who received corticosteroids, the prevalence of obesity is 22% and of central obesity is 50%. In a comparison of SSNS and SRNS groups, cumulative steroid dose as well as risks of obesity and central obesity do not significantly differ between groups.


2018 ◽  
Vol 71 (3) ◽  
pp. 399-406 ◽  
Author(s):  
Adebowale Adeyemo ◽  
Christopher Esezobor ◽  
Adaobi Solarin ◽  
Asiri Abeyagunawardena ◽  
Jameela A. Kari ◽  
...  

2019 ◽  
Vol 35 (4) ◽  
pp. 621-623
Author(s):  
Lale Guliyeva ◽  
Yılmaz Tabel ◽  
Ali Düzova ◽  
Nusret Akpolat ◽  
Seza Özen ◽  
...  

Nephron ◽  
2021 ◽  
pp. 1-6
Author(s):  
Suramath Isaranuwatchai ◽  
Ankanee Chanakul ◽  
Chupong Ittiwut ◽  
Chalurmpon Srichomthong ◽  
Vorasuk Shotelersuk ◽  
...  

Chronic kidney disease of unknown etiology (CKDu) has been a problem in renal practice as indefinite diagnosis may lead to inappropriate management. Here, we report a 54-year-old father diagnosed with CKDu at 33 years old and his 8-year-old son with steroid-resistant nephrotic syndrome. Using whole-exome sequencing, both were found to be heterozygous for c.737G>A (p.Arg246Gln) in LMX1B. The diagnosis of LMX1B-associated nephropathy has led to changes in the treatment plan with appropriate genetic counseling. The previously reported cases with this particular mutation were also reviewed. Most children with LMX1B-associated nephropathy had nonnephrotic proteinuria with normal renal function. Interestingly, our pediatric case presented with steroid-resistant nephrotic syndrome at 8 years old and progressed to ESRD requiring peritoneal dialysis at the age of 15 years. Our report emphasized the need of genetic testing in CKDu for definite diagnosis leading to precise management.


2016 ◽  
Vol 31 (suppl_1) ◽  
pp. i353-i353
Author(s):  
Beata S. Lipska-Ziętkiewicz ◽  
Olivia Boyer ◽  
Olivier Gribouval ◽  
Mansoureh Tabatabaei ◽  
Cecile Fourrage ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document